Literature DB >> 27166196

Lysophosphatidic acid stimulates epithelial to mesenchymal transition marker Slug/Snail2 in ovarian cancer cells via Gαi2, Src, and HIF1α signaling nexus.

Ji Hee Ha1,2, Jeremy D Ward2, Rangasudhagar Radhakrishnan1, Muralidharan Jayaraman1,2, Yong Sang Song3, Danny N Dhanasekaran1,2.   

Abstract

Recent studies have identified a critical role for lysophosphatidic acid (LPA) in the progression of ovarian cancer. Using a transcription factor activation reporter array, which analyzes 45 distinct transcription factors, it has been observed that LPA observed robustly activates the transcription factor hypoxia-induced factor-1α (HIF1α) in SKOV3.ip ovarian cancer cells. HIF1α showed 150-fold increase in its activation profile compared to the untreated control. Validation of the array analysis indicated that LPA stimulates a rapid increase in the levels of HIF1α in ovarian cancer cells, with an observed maximum level of HIF1α-induction by 4 hours. Our report demonstrates that LPA stimulates the increase in HIF1α levels via Gαi2. Consistent with the role of HIF1α in epithelial to mesenchymal transition (EMT) of cancer cells, LPA stimulates EMT and associated invasive cell migration along with an increase in the expression levels N-cadherin and Slug/Snail2. Using the expression of Slug/Snail2 as a marker for EMT, we demonstrate that the inhibition of Gαi2, HIF1α or Src attenuates this response. In line with the established role of EMT in promoting invasive cell migration, our data demonstrates that the inhibition of HIF1α with the clinically used HIF1α inhibitor, PX-478, drastically attenuates LPA-stimulates invasive migration of SKOV3.ip cells. Thus, our present study demonstrates that LPA utilizes a Gαi2-mediated signaling pathway via Src kinase to stimulate an increase in HIF1α levels and downstream EMT-specific factors such as Slug, leading to invasive migration of ovarian cancer cells.

Entities:  

Keywords:  EMT; HIF1α; LPA; metastasis; ovarian cancer

Mesh:

Substances:

Year:  2016        PMID: 27166196      PMCID: PMC5122340          DOI: 10.18632/oncotarget.9224

Source DB:  PubMed          Journal:  Oncotarget        ISSN: 1949-2553


  73 in total

Review 1.  TGF-beta and epithelial-to-mesenchymal transitions.

Authors:  Jiri Zavadil; Erwin P Böttinger
Journal:  Oncogene       Date:  2005-08-29       Impact factor: 9.867

Review 2.  The role of hypoxia inducible factor-1alpha in gynecological cancer.

Authors:  Laura M S Seeber; Nicole Horrée; Marc A G G Vooijs; A Peter M Heintz; Elsken van der Wall; René H M Verheijen; Paul J van Diest
Journal:  Crit Rev Oncol Hematol       Date:  2010-06-07       Impact factor: 6.312

Review 3.  Regulatory networks defining EMT during cancer initiation and progression.

Authors:  Bram De Craene; Geert Berx
Journal:  Nat Rev Cancer       Date:  2013-02       Impact factor: 60.716

4.  The SLUG zinc-finger protein represses E-cadherin in breast cancer.

Authors:  Karen M Hajra; David Y-S Chen; Eric R Fearon
Journal:  Cancer Res       Date:  2002-03-15       Impact factor: 12.701

5.  In vivo tumor growth of high-grade serous ovarian cancer cell lines.

Authors:  Anirban K Mitra; David A Davis; Sunil Tomar; Lynn Roy; Hilal Gurler; Jia Xie; Daniel D Lantvit; Horacio Cardenas; Fang Fang; Yueying Liu; Elizabeth Loughran; Jing Yang; M Sharon Stack; Robert E Emerson; Karen D Cowden Dahl; Maria V Barbolina; Kenneth P Nephew; Daniela Matei; Joanna E Burdette
Journal:  Gynecol Oncol       Date:  2015-06-05       Impact factor: 5.482

6.  Transactivation of platelet-derived growth factor receptor alpha by the GTPase-deficient activated mutant of Galpha12.

Authors:  Rashmi N Kumar; Ji Hee Ha; Rangasudhagar Radhakrishnan; Danny N Dhanasekaran
Journal:  Mol Cell Biol       Date:  2006-01       Impact factor: 4.272

7.  Galpha13 stimulates cell migration through cortactin-interacting protein Hax-1.

Authors:  V Radhika; Djamila Onesime; Ji Hee Ha; N Dhanasekaran
Journal:  J Biol Chem       Date:  2004-08-31       Impact factor: 5.157

8.  Hypoxia attenuates the expression of E-cadherin via up-regulation of SNAIL in ovarian carcinoma cells.

Authors:  Tsutomu Imai; Akiko Horiuchi; Cuiju Wang; Kenji Oka; Satoshi Ohira; Toshio Nikaido; Ikuo Konishi
Journal:  Am J Pathol       Date:  2003-10       Impact factor: 4.307

9.  Lysophosphatidic acid induces STAT3 phosphorylation and ovarian cancer cell motility: their inhibition by curcumin.

Authors:  Ji Hye Seo; Kang Jin Jeong; Woo Jin Oh; Hae Jeong Sul; Jang Sihn Sohn; Yong Kee Kim; Do Yeun Cho; Jae Ku Kang; Chang Gyo Park; Hoi Young Lee
Journal:  Cancer Lett       Date:  2009-07-31       Impact factor: 8.679

10.  Inhibition of HIF-1α by PX-478 enhances the anti-tumor effect of gemcitabine by inducing immunogenic cell death in pancreatic ductal adenocarcinoma.

Authors:  Tiansuo Zhao; He Ren; Li Jia; Jing Chen; Wen Xin; Fan Yan; Jing Li; Xiuchao Wang; Song Gao; Dong Qian; Chongbiao Huang; Jihui Hao
Journal:  Oncotarget       Date:  2015-02-10
View more
  26 in total

Review 1.  Platelets as crucial partners for tumor metastasis: from mechanistic aspects to pharmacological targeting.

Authors:  Annalisa Contursi; Angela Sacco; Rosalia Grande; Melania Dovizio; Paola Patrignani
Journal:  Cell Mol Life Sci       Date:  2017-05-09       Impact factor: 9.261

2.  Increased expression of monoamine oxidase A is associated with epithelial to mesenchymal transition and clinicopathological features in non-small cell lung cancer.

Authors:  Fei Liu; Liang Hu; Yuefan Ma; Bingyu Huang; Zihan Xiu; Peihua Zhang; Keyuan Zhou; Xudong Tang
Journal:  Oncol Lett       Date:  2017-12-21       Impact factor: 2.967

Review 3.  Regulation of tumor cell - Microenvironment interaction by the autotaxin-lysophosphatidic acid receptor axis.

Authors:  Gabor J Tigyi; Junming Yue; Derek D Norman; Erzsebet Szabo; Andrea Balogh; Louisa Balazs; Guannan Zhao; Sue Chin Lee
Journal:  Adv Biol Regul       Date:  2018-09-16

4.  Coiled-coil domain containing 109B is a HIF1α-regulated gene critical for progression of human gliomas.

Authors:  Ran Xu; Mingzhi Han; Yangyang Xu; Xin Zhang; Chao Zhang; Di Zhang; Jianxiong Ji; Yuzhen Wei; Shuai Wang; Bin Huang; Anjing Chen; Qing Zhang; Wenjie Li; Tao Sun; Feng Wang; Xingang Li; Jian Wang
Journal:  J Transl Med       Date:  2017-07-28       Impact factor: 5.531

Review 5.  Complex Determinants of Epithelial: Mesenchymal Phenotypic Plasticity in Ovarian Cancer.

Authors:  Yuliya Klymenko; Oleg Kim; M Sharon Stack
Journal:  Cancers (Basel)       Date:  2017-08-09       Impact factor: 6.639

6.  Gene regulatory networking reveals the molecular cue to lysophosphatidic acid-induced metabolic adaptations in ovarian cancer cells.

Authors:  Upasana Ray; Shreya Roy Chowdhury; Madavan Vasudevan; Kiran Bankar; Susanta Roychoudhury; Sib Sankar Roy
Journal:  Mol Oncol       Date:  2017-04-03       Impact factor: 6.603

Review 7.  Lysophosphatidic acid (LPA) as a pro-fibrotic and pro-oncogenic factor: a pivotal target to improve the radiotherapy therapeutic index.

Authors:  Chloé Rancoule; Sophie Espenel; Jane-Chloé Trone; Julien Langrand-Escure; Alexis Vallard; Amel Rehailia-Blanchard; Anis El Meddeb Hamrouni; Yaxiong Xia; Jean-Baptiste Guy; Majed Ben-Mrad; Nicolas Magné
Journal:  Oncotarget       Date:  2017-06-27

8.  LPA Induces Metabolic Reprogramming in Ovarian Cancer via a Pseudohypoxic Response.

Authors:  Ji Hee Ha; Rangasudhagar Radhakrishnan; Muralidharan Jayaraman; Mingda Yan; Jeremy D Ward; Kar-Ming Fung; Katherine Moxley; Anil K Sood; Ciro Isidoro; Priyabrata Mukherjee; Yong Sang Song; Danny N Dhanasekaran
Journal:  Cancer Res       Date:  2018-01-31       Impact factor: 12.701

9.  Discoidin Domain Receptor 2 Mediates Lysophosphatidic Acid-Induced Ovarian Cancer Aggressiveness.

Authors:  Bo Young Jeong; Kyung Hwa Cho; Se-Hee Yoon; Chang Gyo Park; Hwan-Woo Park; Hoi Young Lee
Journal:  Int J Mol Sci       Date:  2021-05-20       Impact factor: 5.923

10.  EDG2 enhanced the progression of hepatocellular carcinoma by LPA/PI3K/AKT/ mTOR signaling.

Authors:  Meng Xu; Zhikui Liu; Cong Wang; Bowen Yao; Xin Zheng
Journal:  Oncotarget       Date:  2017-08-02
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.